BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral treprostinil: Completed Phase III enrollment

United Therapeutics completed enrollment of 349 PAH patients in the 12-week, double-blind, placebo-controlled, international Phase III FREEDOM-M trial evaluating twice-daily oral treprostinil. United Therapeutics markets IV and subcutaneous...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >